Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 858, pseudogene (RNU6-858P) is classified as a processed pseudogene of the U6 small nuclear RNA family[1][6]. The U6 snRNA is an essential component of the spliceosome and is highly conserved, but pseudogenes like RNU6-858P lack the ability to encode functional RNA due to mutations or absence of regulatory sequences necessary for proper expression and processing[4][7]. Such pseudogenes are considered evolutionary relics and generally do not produce functional molecules, though some may have regulatory roles at the RNA level (e.g., as antisense RNAs or competing endogenous RNAs), though no such function has been specifically ascribed to RNU6-858P[4][8]. There is no evidence that RNU6-858P acts as a drug target, biomarker, or is associated directly with human disease[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 858, pseudogene (RNU6-858P).